4.7 Article

Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation

Journal

CELL STEM CELL
Volume 21, Issue 3, Pages 319-+

Publisher

CELL PRESS
DOI: 10.1016/j.stem.2017.07.009

Keywords

-

Funding

  1. NIH [R01MH108528, R01MH094753, R01MH109885, R01MH100175, R21MH107771, R56MH109587, U19MH107367]
  2. Ruth L. Kirschstein NRSA Fellowship [1F31NS076198]
  3. California Institute for Regenerative Medicine (CIRM) award [DISC1-08825]
  4. UCSD CTRI pilot grant
  5. NARSAD Independent Investigator Grant
  6. European Research Council [GA 309449]
  7. ERA-NET Neuron [MR/M501803/1]
  8. National Research Agency (France) [ANR-10-IAHU-01]
  9. Roche Postdoc Fellowship Program (F. Hoffmann-La Roche)
  10. Medical Research Council [MR/M501803/1] Funding Source: researchfish
  11. MRC [MR/M501803/1] Funding Source: UKRI

Ask authors/readers for more resources

Three-prime repair exonuclease 1 (TREX1) is an anti-viral enzyme that cleaves nucleic acids in the cytosol, preventing accumulation and a subsequent type I interferon-associated inflammatory response. Autoimmune diseases, including Aicardi-Goutieres syndrome (AGS) and systemic lupus erythematosus, can arise when TREX1 function is compromised. AGS is a neuroinflammatory disorder with severe and persistent intellectual and physical problems. Here we generated a human AGS model that recapitulates disease-relevant phenotypes using pluripotent stem cells lacking TREX1. We observed abundant extrachromosomal DNA in TREX1-deficient neural cells, of which endogenous Long Interspersed Element-1 retrotransposons were a major source. TREX1-deficient neurons also exhibited increased apoptosis and formed three-dimensional cortical organoids of reduced size. TREX1-deficient astrocytes further contributed to the observed neurotoxicity through increased type I interferon secretion. In this model, reverse-transcriptase inhibitors rescued the neurotoxicity of AGS neurons and organoids, highlighting their potential utility in therapeutic regimens for AGS and related disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available